Hongli Yin

1 Introduction The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is ≈38%, causing serious healthy burdens worldwide.[1, 2] Currently, for the treatment of MASLD, endocrine hormones, including thyroid hormone, glucagon like peptide-1 (GLP-1), and fibroblast growth factor-21 (FGF21), have attracted significant attentions. Various therapeutic strategies have been developed based on them.

The human cell lines HOS,143B, U2OS, MG-63, and 293FT were purchased from Procell Life Science & Technology and FuHeng Biology. 293T and U2OS cells (Procell, CL-0005; Procell, CL-0236) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, BasalMedia). HOS,143B and MG-63 cells (FuHeng, FH0440; FuHeng, FH0438; Procell, CL-0157) were grown in Minimum Essential Medium alpha (MEM-α, BasalMedia). All the cell lines were tested for authentication using short tandem repeat fingerprinting.

The human GBM cell lines U87, A172, LN229, and U251 were purchased from the ATCC (USA). The cells were grown in Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum, 100 units/ml streptomycin, and 100 μg/ml penicillin.